Clinical trial design in haemophilia.
(2012) In Haemophilia 18 Suppl 4. p.18-23- Abstract
- Summary:
Progress in the evidence-based care of haemophilia A and B worldwide has been historically challenged by the dearth of evaluable outcome data, including but not limited to the safety and effectiveness of therapeutic interventions. These challenges are partially rooted in the inherent difficulty of conducting prospective clinical trials and observational studies with statistically meaningful endpoints in a rare disease such as haemophilia. Despite the logistical barriers, the need for outcome data has never been more critical than in this time of expansive therapeutic advance tempered by the shrinking economic capacity to fund the rapidly increasing cost of treatment. Given that systematic analyses of published literature... (More) - Summary:
Progress in the evidence-based care of haemophilia A and B worldwide has been historically challenged by the dearth of evaluable outcome data, including but not limited to the safety and effectiveness of therapeutic interventions. These challenges are partially rooted in the inherent difficulty of conducting prospective clinical trials and observational studies with statistically meaningful endpoints in a rare disease such as haemophilia. Despite the logistical barriers, the need for outcome data has never been more critical than in this time of expansive therapeutic advance tempered by the shrinking economic capacity to fund the rapidly increasing cost of treatment. Given that systematic analyses of published literature have been largely unsuccessful in compensating for the lack of rigorous and purposeful data collection, new approaches to clinical study design and statistical modelling are urgently needed. However, even as these are considered, the lack of broadly accepted and well-defined clinical outcome endpoints poses an additional barrier to progress. The three presentations encompassed by this paper highlight the timely need for quality data from the perspectives of the clinicians, regulatory agencies and health care funders, and describe the ongoing coordinated efforts by the international haemophilia community to further understand and dismantle the barriers to harmonized and standardized data collection on a global scale using well-defined clinical outcome endpoints. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2858931
- author
- Dimichele, D M ; Blanchette, V and Berntorp, Erik LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Haemophilia
- volume
- 18 Suppl 4
- pages
- 18 - 23
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000305605400003
- pmid:22726077
- scopus:84862889106
- ISSN
- 1351-8216
- DOI
- 10.1111/j.1365-2516.2012.02824.x
- language
- English
- LU publication?
- yes
- id
- 22b33636-b16b-49c4-8b9a-0bc18fe7cf46 (old id 2858931)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22726077?dopt=Abstract
- date added to LUP
- 2016-04-04 08:06:54
- date last changed
- 2022-08-08 06:59:25
@article{22b33636-b16b-49c4-8b9a-0bc18fe7cf46,
abstract = {{Summary:<br/><br>
Progress in the evidence-based care of haemophilia A and B worldwide has been historically challenged by the dearth of evaluable outcome data, including but not limited to the safety and effectiveness of therapeutic interventions. These challenges are partially rooted in the inherent difficulty of conducting prospective clinical trials and observational studies with statistically meaningful endpoints in a rare disease such as haemophilia. Despite the logistical barriers, the need for outcome data has never been more critical than in this time of expansive therapeutic advance tempered by the shrinking economic capacity to fund the rapidly increasing cost of treatment. Given that systematic analyses of published literature have been largely unsuccessful in compensating for the lack of rigorous and purposeful data collection, new approaches to clinical study design and statistical modelling are urgently needed. However, even as these are considered, the lack of broadly accepted and well-defined clinical outcome endpoints poses an additional barrier to progress. The three presentations encompassed by this paper highlight the timely need for quality data from the perspectives of the clinicians, regulatory agencies and health care funders, and describe the ongoing coordinated efforts by the international haemophilia community to further understand and dismantle the barriers to harmonized and standardized data collection on a global scale using well-defined clinical outcome endpoints.}},
author = {{Dimichele, D M and Blanchette, V and Berntorp, Erik}},
issn = {{1351-8216}},
language = {{eng}},
pages = {{18--23}},
publisher = {{Wiley-Blackwell}},
series = {{Haemophilia}},
title = {{Clinical trial design in haemophilia.}},
url = {{http://dx.doi.org/10.1111/j.1365-2516.2012.02824.x}},
doi = {{10.1111/j.1365-2516.2012.02824.x}},
volume = {{18 Suppl 4}},
year = {{2012}},
}